Development of a Serum Biomarker Assay That Differentiates Tumor-Associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC

Figure 4

NPC-1C antigen detection in patients undergoing treatment. Serial blood draws of cancer patients over an approximate 3-month period were tested. The NPC-1C sandwich ELISA was performed at a 1 : 24 serum dilution as described in Section 2. Results are presented as a scatter plot of each experimental group, with the mean and standard error of the mean. There were 28 normal sera, 41 colorectal/pancreatic cancer sera at 1-month, 33 colorectal/pancreatic cancer sera at 2-month, and 25 colorectal/pancreatic cancer sera at 3-month.